Maximum androgen blockade
Maximum androgen blockade (MAB) or complete or combined androgen blockade (CAB) is a medical treatment involving the combination of both androgen receptor (AR) antagonism and inhibition or suppression of androgen production to attain maximal effectiveness in androgen deprivation therapy.[1] An example of MAB is the combination of bicalutamide, an AR antagonist, with a gonadotropin-releasing hormone (GnRH) GnRH analogue such as leuprorelin or cetrorelix.[1] Cyproterone acetate and galeterone are examples of MAB that combine both mechanisms into a single drug. MAB was developed for and is employed in the treatment of prostate cancer.[1]
References
|
This article is issued from Wikipedia - version of the Wednesday, March 09, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.